Effect of fucoxanthin alone and in combination with d-glucosamine hydrochloride on carrageenan/kaolin-induced experimental arthritis in rats

Phytotherapy Research

Volumn 28, Issue 7, 2014, Pages 1054-1063

  Gong, Dezheng ^a   Chu, Wanjiang ^a   Jiang, Liping ^a   Geng, Chengyan ^a   Li, Jing ^a   Ishikawa, Nobuyuki ^b   Kajima, Koji ^b   Zhong, Laifu ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

anti arthritis; antiinflammatory; cytokine; fucoxanthin (FUCO); proteoglycan (PG)

Indexed keywords

CARRAGEENAN; CYCLOOXYGENASE 2; DICLOFENAC; FUCOXANTHIN; GLUCOSAMINE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; KAOLIN; PROTEOGLYCAN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASSAY; CARTILAGE DEGENERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL ARTHRITIS; GRIESS REAGENT ASSAY; HISTOPATHOLOGY; JOINT SWELLING; MALE; MUSCLE ATROPHY; MUSCLE MASS; NONHUMAN; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; RAT; SYNOVIUM; UPREGULATION; WESTERN BLOTTING;

ANTI-ARTHRITIS; ANTIINFLAMMATORY; CYTOKINE; FUCOXANTHIN (FUCO); PROTEOGLYCAN (PG);

ANIMALS; ARTHRITIS, EXPERIMENTAL; CARRAGEENAN; CYCLOOXYGENASE 2; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLUCOSAMINE; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-1BETA; KAOLIN; KNEE JOINT; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PROTEOGLYCANS; RATS; RATS, SPRAGUE-DAWLEY; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA; XANTHOPHYLLS;

EID: 84904210223     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5093     Document Type: Article

References (42)

1. Beppu F, Niwano Y, Tsukui T, Hosokawa M, Miyashita K,. 2009a. S ingle and repeated oral dose toxicity study of fucoxanthin, a marine carotenoid, in mice. J Toxicol Sci 5: 501-510.
2. Beppu F, Niwano Y, Sato E, et al,. 2009b. In vitro and in vivo evaluation of mutagenicity of fucoxanthin and its metabolite fucoxanthinol. J Toxicol Sci 6: 693-698.
3. Beren J, Hill SL, Diener-West M, Rose NR,. 2001. Effect of pre-loading oral glucosamine HCl/chondroitin sulfate/manganese ascorbate combination on experimental arthritis in rats. Exp Biol Med 226: 144-151.
4. Brennan FM, Mclnnes IB,. 2008. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 118: 3537-3545.
5. Choy EH, Panayi GS,. 2001. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344: 907-916. (Pubitemid 32224400)
6. de los Reyes GC, Koda RT, Lien EJ,. 2000. Glucosamine and chondroitin sulfates in the treatment of osteoarthritis. Prog Drug Res 55: 81-103.
7. Day SM, Lockhart JC, Ferrell WR, Mclean JS,. 2004. Divergent roles of nitrergic and prostanoid pathways in chronic joint inflammation. Ann Rheumatoid Dis 63: 1564-1570. (Pubitemid 39573682)
8. Dayer JM,. 2003. The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatology 42 (Suppl.2): ii3-ii10.
9. Fenton JI, Chlebek-Brown KA, Peters TL, Caron JP, Orth MW,. 2000. Glucosamine HCl reduces equine artilage degradation in explant culture. Osteoarthritis Cartilage 8: 258-265. (Pubitemid 30620187)
10. Fleischmann R, Stern R, Iqba I,. 2004. Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis. Expert Opin Biol Ther 4: 1333-1344. (Pubitemid 39005738)
11. Heo SJ, Yoon WJ, Kim KN, et al,. 2010. Evaluation of anti-inflammatory effect of fucoxanthin isolated from brown algae in lipopolysaccharide-stimulated RAW 264.7 macrophages. Food Chem Toxicol 48: 2045-2051.
12. Hua J, Sugruo S, Hirano S, Sakamoto K, Nagaoka I,. 2005. Preventive actions of a high dose of glucosamine on adjuvant arthritis in rats. Inflamm Res 54: 127-132. (Pubitemid 40767560)
13. Ivanovska N, Dimitrova P,. 2011. Bone resorption and remodeling in murine collagenase-induced osteoarthritis after administration of glucosamine. Arthritis Res Ther 13: R44.
14. Jean YH, Chen WF, Duh CY, et al,. 2008. Inducible nitric oxide synthase cyclooxygenase-2 participates in anti-inflammatory and analgesic effects of the natural marine compound lemnalol from Formosa soft coral Lemnalia cervicorni. Eur J Pharm 578: 323-331.
15. Joosten ABE, Lubberts E, Helsen MMA, et al,. 1999. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis. Arthritis Res 1: 81-91. (Pubitemid 32223676)
16. Khanna D, Sethi G, Ahn KS, et al,. 2007. Natural products as a gold mine for arthritis treatment. Curr Opin Pharmacol 7: 344-351. (Pubitemid 46731200)
17. Kim KN, Heo SJ, Yoon WJ, et al,. 2010. Fucoxanthin inhibits the inflammatory response by suppressing the activation of NF-kB and MAPKs in lipopolysaccharide-induced RAW 264.7 macrophages. Eur J Pharmacol 649: 369-375.
18. Kinne RW, Brauer R, Stuhlmuller B, Palombo-Kinne E, Burmester GR,. 2000. Review: macrophages in rheumatoid arthritis. Arthritis Res 2: 189-202.
19. Lundeberg TP, Alstergren P, Appelgren A, et al,. 1996. A model for experimentally induced temperomandibular joint arthritis in rats: effects of carrageenan on neuropeptide-like immunoreactivity. Neuropeptides 30: 37-41. (Pubitemid 26086432)
20. Mangge H, Gindl S, Kenzian H, Schauenstein K,. 2003. Atopic dermatitis as a side effect of anti-tumor necrosis factor-alpha therapy. J Rheumatol 30: 2506-2507. (Pubitemid 37413916)
21. Mclnnes IB, Leung BP, Field M, et al,. 1996. Production of nitric oxide in the synovial membrane of rheumatoid and osteoarthritis patients. J Exp Med 184: 1519-1524. (Pubitemid 26354707)
22. Meulyzer M, Vachon P, Beaudry F, et al,. 2009. Joint inflammation increases glucosamine levels attained in synovial fluid following oral administration of glucosamine hydrochloride. Osteoarthritis Cartilage 17: 228-234.
23. Nakamura H, Masuko K, Yudoh K, Kato T, Kamada T, Kawahara T,. 2007. Effects of glucosamine administration on patients with rheumatoid arthritis. Rheumatol Int 27: 213-218. (Pubitemid 46088250)
24. 2, nitric oxide and metalloproteases by chondrocytes and synoviocytes in osteoarthritis. Clin Exp Rheumatol 22: 293-299. (Pubitemid 38585231)
25. Oegema TR Jr, Deloria LB, Sandy JD, Hart DA,. 2002. Effect of oral glucosamine on cartilage and meniscus in normal and chymopapain-injected knees of young rabbits. Arthritis Rheum 46: 2495-2503.
26. Penido C, Conte FP, Chagas MSS, Rodrigues CAB, Pereira JFG, Henrigues MGMO,. 2006. Antiinflammatory effects of natural tetranortriterpenoids isolated from Carapa guianensis. Aublet on zymosaninduced arthritis in mice. Inflamm Res 55: 457-464. (Pubitemid 44826734)
27. Plater-Zybert C, Joosten LAB, Helsen MMA, et al,. 2001. Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J Clin Invest 108: 1825-1832. (Pubitemid 34015128)
28. Posadas I, Bucci M, Roviezzo F, et al,. 2004. Carrageenan-induced mouse paw oedema is biphasic, age-weight dependent and displays differential nitric oxide cyclooxygenase-2 expression. Br J Pharmacol 142: 331-338. (Pubitemid 38746169)
29. Rocha Ana CC, Fernandes E, Quintao Nara LM, Campos MM, Calixto JB,. 2006. Relevance of tumour necrosis factor-α for the inflammatory and nociceptive responses evoked by carrageenan in the mouse paw. Br J Pharmacol 148: 688-695. (Pubitemid 43993059)
30. Rooney M, Condell D, Quinlan W, et al,. 1988. Analysis of the histologic variation of synovitis in rheumatoid arthritis. Arthritis Rheum 31: 956-963.
31. Rosengren S, Firestein GS, Boyle DL,. 2003. Measurement of inflammatory biomarkers in synovial tissue extracts by enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 2003: 1002-1010. (Pubitemid 37444265)
32. Scheiman JM,. 2001. The impact of nonsteroidal anti-inflammatory drug-induced gastropathy. Am J Manag Care 7: s10-s14. (Pubitemid 32170770)
33. Schlaak JF, Pfers I, Meyer Zum Buschenfelde KH, Marker-Hermann E,. 1996. Different cytokine profiles in the synovial fluid of patients with osteoarthritis, rheumatoid arthritis and seronegative spondylarthropathies. Clin Exp Rheumatol 49: 155-162. (Pubitemid 26160127)
34. Setnikar I, Giacchetti C, Zanolo G,. 1986. Pharmacokinetics of glucosamine in the dog and man. Arzneimittelforschung 36: 729-735.
35. Shiratori K, Ohgami K, Ilieva I, et al,. 2005. Effects of fucoxanthin on lipopolysaccharide-induced inflammation in vitro and in vivo. Exp Eye Res 81: 422-428. (Pubitemid 41356505)
36. Silva JC, Rocha MF, Lima AA, Brito GA, de Menezes DB, Rao VS,. 2000. Effects of pentoxifylline and nabumetone on the serum levels of IL-1 beta and TNF in the joints of adjuvant arthritis. Inflamm Res 49: 14-19. (Pubitemid 30073181)
37. Silvan AM, Abad MJ, Bermejo P, Villar AM, Lopez-Bote JP,. 1996. Aggravation of adjuvant arthritis by carrageenan. Gen Pharmacol 27: 639-642. (Pubitemid 26233334)
38. Teas J,. 1983. The dietary intake of Laminaria, a brown sea weed, and breast cancer prevention. Nutr Cancer 4: 217-222. (Pubitemid 13136331)
39. Vinegar R, Truax JF, Selph JL, Johnston PR, Venable AL, Mckenzie KK,. 1987. Pathway to carrageenan-induced inflammation in the hind limb of the rat. Fed Proc 46: 118-126.
40. Wang WJ, Wang GC, Zhang M, Tseng CK,. 2005. Isolation of fucoxanthin from the rhizoid of Laminaria japonica Aresch. J Integr Plant Biol 47: 1009-1015. (Pubitemid 41762651)
41. Wehling N, Palmer GD, Pilapil C, et al,. 2009. Interleukin-1β and tumor necrosis factor α inhibit chondrogenesis by human mesenchymal stem cells through NF-κB-dependent pathways. Arthritis Rheum 3: 801-812.
42. Yan X, Chuda Y, Suzuki M, Nagata T,. 1999. Fucoxanthin as the major antioxidant in Hijikia fusiformis, a common edible seaweed. Biotechnol Biochem 63: 605-607. (Pubitemid 129555518)